Industry pioneer and world-renowned green chemist John Warner reflects on his journey to Zymergen.
Industry pioneer and world-renowned chemist John Warner has joined the Zymergen team as a Distinguished Research Fellow. John is a global leader in green chemistry, with hundreds of patents to his name, and a prominent academic figure who brought green chemistry to the mainstream.
The outbreak of COVID-19 is fueling an urgent need for discovery and development, particularly around medicine, testing and materials – all highly dependent on biology. Many private organizations and government agencies are working together, and teams of scientists across borders are breaking their culture of secrecy and competitive advantage to partner up, openly sharing data to solve major problems fast.
On Wednesday morning, Zymergen announced our first standalone, commercially available product called HYALINE – a revolutionary bio-generated specialty film in the polyimide family.
Earlier today we announced the release of HYALINE - a revolutionary new bio-fabricated film that we believe will completely transform the electronics industry. Developed in partnership with Sumitomo Chemical, the Hyaline products have been successfully tested in flexible circuits, display touch sensors and printable electronics.
By merging enEvolv’s powerful platform technology with our existing genome engineering, automation and machine learning capabilities, we will dramatically improve our ability to discover, design and commercialize breakthrough biologically-manufactured products.
The World Economic Forum and McKinsey recently published a whitepaper in which they recognize Zymergen as a “lighthouse company”, helping drive what they characterize as the Fourth Industrial Revolution (they also presented us with a lighthouse award, which a number of my colleagues shared from Davos).
At Zymergen, we use biology to create never-before imagined materials. As we continue to scale and build our growing pipeline of next generation products, we’re proud to announce that we’ve appointed Jay Flatley, Chairman of the Board of Illumina, and Sandra E. Peterson, former Group Worldwide Chairman for Johnson & Johnson, to Zymergen’s Board of Directors. Jay will serve as Lead Independent Director.
At Zymergen, we apply AI or machine learning techniques to many aspects of our high-throughput microbial genome assembly and testing systems and practices. Aaron Kimball, our CTO, offers his thoughts on what lessons we’ve learned as a result of this AI journey, and how these can be generalized to a broader business context.
At Zymergen, we apply AI or machine learning techniques to many aspects of our high-throughput microbial genome assembly and testing systems and practices. Aaron Kimball, our CTO, offers his thoughts on what lessons we’ve learned as a result of this AI journey, and how these can be generalized to a broader business context. In this two-part series, we will discuss first the opportunities and benefits brought to organizations by the use of AI.